It was reported that the survival rate of patients with lung cancer decreased when ANXA2 was up-regulated, which might serve as a potentail biomarker for NSCLC (Agababaoglu et al., 2017; Wang et al., 2012). This evidence concerns the gene ANXA2 and lung carcinoma.